212 related articles for article (PubMed ID: 20425329)
1. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
Raza A; Buonamici S; Lisak L; Tahir S; Li D; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G
Leuk Res; 2004 Aug; 28(8):791-803. PubMed ID: 15203277
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
6. New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Sekeres MA
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365
[TBL] [Abstract][Full Text] [Related]
7. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
[TBL] [Abstract][Full Text] [Related]
8. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide for the treatment of myelodysplastic syndromes.
Vey N
Expert Opin Pharmacother; 2004 Mar; 5(3):613-21. PubMed ID: 15013929
[TBL] [Abstract][Full Text] [Related]
10. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
[No Abstract] [Full Text] [Related]
11. New approaches to the treatment of myelodysplasia.
List AF
Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenesis in myelodysplastic syndrome.
Aguayo A; Armillas-Canseco FM; Martínez-Baños D
Curr Cancer Drug Targets; 2011 Nov; 11(9):1044-52. PubMed ID: 21999628
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
17. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Galimberti S; Guerrini F; Salvi F; Petrini I; Gioia D; Messa E; Palumbo GA; Cilloni D; Petrini M; Levis A
J Hematol Oncol; 2012 Sep; 5():53. PubMed ID: 22964015
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
